The German-Australian AML Study Group, one of the largest global groups evaluating treatments for acute myeloid leukemia (AML), has published results in the New England Journal of Medicine that now classifies AML into 11 classes based on the harbored genetic mutations.
The German-Australian AML Study Group (AMLSG), one of the largest global groups evaluating treatments for acute myeloid leukemia (AML), has published results in the New England Journal of Medicine that now classifies AML into 11 classes.
AMLSG obtained samples from patients participating in 3 different prospective multicenter trials for AML: AML-HD98A, AML-HD98B, and AMLSG-07-04. The age group of the study cohort was significantly different for AML-HD98B (58 to 84 years) compared with AML-HD98A (18 to 65 years) and AMLSG-07-04 (18 to 61 years). The patients received the following treatments:
Patient samples were evaluated for somatic driver mutations to generate a new genetic approach to disease classification, one that could have prognostic implications. Cytogenetic analyses of the patient samples involved the sequencing of 111 genes to identify a host of driver mutations:
More than 5000 driver mutations in 76 genes were identified through the study, in 1540 patient samples—a majority (73%) were point mutations. Ninety-six percent of samples had at least 1 driver mutation, and 86% samples had 2 or more. Gene-paired mutations or co-mutations led to the disease being classified into 11 classes, each of which, the authors write, have distinct diagnostic features and clinical outcomes. While 8 classes are already known, 3 heterogeneous genomic categories evolved from this study:
The study also found that mutations in DNMT3A, ASXL1, IDH1/2, and TET2, genes that encode epigenetic modifiers, were acquired the earliest. These mutations were more common in elderly persons and conferred an increased risk of hematologic malignancies. Mutations in the receptor tyrosine kinase—RAS pathway genes usually occurred later and often more than once in the same patient. Mutations in the NPM1 gene often followed DNMT3A, IDH1, or NRAS mutations.
This evolutionary trajectory of genetic mutations that drive AML mirrors the observations in pancreatic cancer.
“The driver landscape in AML reveals distinct molecular subgroups that reflect discrete paths in the evolution of AML, informing disease classification and prognostic stratification,” the authors conclude of their findings.
Reference
Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209-2221. doi:10.1056/NEJMoa1516192.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More